Severe asthma during the COVID-19 pandemic: Clinical observations

Haroun‐Díaz, Elisa; Torre, María Vázquez de la; Pérez, Francisco Javier Ruano; Álvarez, Maria Luisa Somoza; Alzate, Diana Pérez; González, Paula López; Prieto-Moreno, Ana; Rojas, Isabel Torres; García, María Desamparados Cervera; Blanca‐López, Natalia; Díez, Gabriela Canto

doi:10.1016/j.jaip.2020.06.033

Cited by 15 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the case that severe asthma patients contracted the disease, this study suggests they would have shown very weak to no symptoms. The thesis is also supported by Haroun-Diaz et al [14]. Reasoning for this include a series of factors recently studied in the wake of COVID -19 pandemic.…”

Section: Resultsmentioning

confidence: 82%

“…This same evidence has been reported by Haroun-Diaz et al in Madrid, Spain, where the disease has had a much greater impact. 14 The main limitation of this study is that exact prevalence of the disease in these patients cannot be known, as most of the patients did not have a RT-PCR or serological test done; however taking into account that until June, diagnostic tests were only done to patients with moderate to severe symptoms who required hospitalization, exact prevalence of COVID-19 in our population is unknown. The next step is to perform total antibody serological test to the 106 patients, in order to determine exact prevalence, taking into consideration the high sensitivity of the test (86.43%) and its high specificity (99.57%).…”

Section: Resultsmentioning

confidence: 95%

See 1 more Smart Citation

Examining Wether Personal Characteristics in Severe Asthma Patients Increase the Probability of Being Infected by Covid-19

Farzanegan

Llamazares

pez

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The pandemic caused by Coronavirus disease 2019, has caused great impact worldwide. Risk factors for severe outcomes have been identified, but asthma seems not to be one of them. Objectives: Our principal purpose is to analyze personal characteristics in severe asthma patients, in treatment with monoclonal antibody, belonging to the Health Department of Castellon, in order to see if these variables affect the probability of being infected by SARS-Cov-2. Methods: This is an observational study. Patients recruited had severe asthma in treatment with monoclonal antibody. A questionnaire was elaborated. Aspects evaluated were: COVID-19 symptoms, asthma control, exposition to the disease, and lifestyle before the pandemic. Serological tests were done by using total SARS-Cov-2 antibody test. Results: 108 patients were enrolled in the study, of whom 106 patients were included. 11 patients declared suggestive COVID-19 symptoms. A total of 21 patients had a serology test done, giving positive results 2 of them. 27 patients needed medical attention, being asthma exacerbation the most common symptom. 71,7% of patients had a normal or high level of social activity before the pandemic. Statistic significance was achieved for medical assistance, asthma control and contact with SARS-Cov-2 positive patients. Conclusion: Personal external factors in severe asthma patients do not influence the probability of being affected by the disease. We can hypothesize that these patients do not have an increased susceptibility for being infected by the virus. Bad asthma control was the main reason for medical assistance during the pandemic.

show abstract

Section: Resultsmentioning

confidence: 82%

Section: Resultsmentioning

confidence: 95%

Examining Wether Personal Characteristics in Severe Asthma Patients Increase the Probability of Being Infected by Covid-19

Farzanegan

Llamazares

pez

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…From the 42 asthmatic patients identified, patients on GINA 4/5 and those not adequately treated were considered at higher risk. Hauron-Diaz et al 35 , in a sample of 80 severe asthma patients followed in the Allergy Service of Infanta Leonor University Hospital (Madrid, Spain), SARS-CoV-2 infection was confirmed in three (3.75%) patients. None of the patients required intensive care.…”

Section: Resultsmentioning

confidence: 97%

Severe asthma in the era of COVID-19: A narrative review

et al. 2022

View full text Add to dashboard Cite

Introduction and objectives: Severe asthma management during the coronavirus disease 2019 (COVID-19) pandemic is a challenge and will continue to be, at least in the next few months, as herd immunity is still a mirage. A lot has to be learned about how COVID-19 affects underlying diseases, and severe asthma is no exception. Methods: Narrative review of papers available until February 2021 in PubMed and Google Scholar, relating severe asthma and COVID-19. Four main research topics were reviewed: SARS-CoV-2 infection: immunology and respiratory pathology; interrelationship of severe asthma endotypes and COVID-19 disease mechanisms; severe asthma epidemiology and COVID-19; and biologics for severe asthma in the context of COVID-19. Results: COVID-19 disease mechanisms start with upper respiratory cell infection, and afterwards several immunological facets are activated, contributing to disease severity, namely cell-mediated immunity and antibody production. Although infrequent in the COVID-19 course some patients develop a cytokine storm that causes organ damage and may lead to acute respiratory distress syndrome or multiorgan failure. Regarding severe asthma endotypes, type2-high might have a protective role both in infection risk and disease course. There is conflicting data regarding the epidemiological relationship between COVID-19 among severe asthma patients, with some studies reporting increased risk of infection and disease course, whereas others the other way round. Biologics for severe asthma do not seem to increase the risk of infection and severe COVID-19, although further evidence is needed. Conclusions: Globally, in the era of COVID-19, major respiratory societies recommend continuing the biologic treatment, preferably in a self-home administration program.

show abstract

“…The severe asthma would not increase the risk of COVID-19 infection and severity [ 46 ]. No patient developed cytokine storm or acute respiratory distress syndrome although 3.8% severe asthma had confirmed COVID-19 [ 47 ]. The epidemiologic study of COVID-19 in China, which included 44,672 confirmed cases of COVID-19, did not identify asthma as a risk factor of COVID-19 severity [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

The impact of comorbid allergic airway disease on the severity and mortality of COVID-19: a systematic review and meta-analysis

Wei

Zuo

Han

et al. 2021

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Purpose To analyze the impact of AAD on the severity and mortality of COVID-19 patients and compare clinical outcomes between patients with and without AAD. Methods In the systematic review and meta-analysis, we searched PubMed, Embase, Web of Science for studies reporting allergic rhinitis, asthma prevalence in COVID-19 patients and compared clinical outcomes, and excluded duplicate publications, reviews, comments, single or few cases reports (< 100 cases). We determined the pooled effect estimates using random effect model. Results Thirty-four studies (345,091) were finally included for the meta-analysis. On the basis of 32 studies (337,821) involving with the severity of COVID-19, we did not find significant association between AAD and the severity of COVID-19 ( p = 0.35, OR 1.10, 95% CI 0.90–1.35). Subgroup analysis indicated there was no the variability in the prevalence of AAD among COVID-19 patients in different study designs, disease categories, countries, the definition of severity, and population size of AAD . Based on 21 studies (306,331) involving with the mortality of COVID-19, AAD was significantly associated with the decreased mortality of COVID-19 ( p < 0.05, OR 0.83, 95% CI 0.70–0.99). The subgroup analysis showed AAD was not associated with the mortality of COVID-19 in different countries or regions. Based on the population size of AAD, we found AAD within 100 cases was not associated with the mortality of COVID-19 ( p = 0.63, OR 1.15, 95% CI 0.65–2.03). Moreover, study design was possible heterogeneity source as the heterogeneity I 2 was reduced to 0 in prospective studies. Conclusion The preexisting AAD was not inclined to deteriorate the course of COVID-19. The prevalence of AAD was not associated with the severity of COVD-19 patients and inclined to be significantly associated with the decreased mortality risk of COVID-19. Supplementary Information The online version contains supplementary material available at 10.1007/s00405-021-07072-1.

show abstract

Severe asthma during the COVID-19 pandemic: Clinical observations

Cited by 15 publications

References 6 publications

Examining Wether Personal Characteristics in Severe Asthma Patients Increase the Probability of Being Infected by Covid-19

Examining Wether Personal Characteristics in Severe Asthma Patients Increase the Probability of Being Infected by Covid-19

Severe asthma in the era of COVID-19: A narrative review

The impact of comorbid allergic airway disease on the severity and mortality of COVID-19: a systematic review and meta-analysis

Contact Info

Product

Resources

About